Detalles de la búsqueda
1.
Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1.
Bioorg Chem
; 139: 106711, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37473479
2.
PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Toxicol Appl Pharmacol
; 398: 115019, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32335126
3.
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.
Bioorg Med Chem Lett
; 28(3): 388-393, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29290542
4.
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Bioorg Med Chem
; 25(24): 6379-6387, 2017 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29089260
5.
Synthesis and evaluation of piperazinotriazoles. Discovery of a potent and orally bioavailable neurokinin-3 receptor inhibitor.
Eur J Med Chem
; 257: 115486, 2023 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247507
6.
Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT2A receptor antagonists/inverse agonists.
Eur J Med Chem
; 234: 114246, 2022 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35279606
7.
Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist.
Eur J Med Chem
; 242: 114679, 2022 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998545
8.
(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.
Front Pharmacol
; 12: 770377, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34950030
9.
Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors.
Eur J Med Chem
; 224: 113718, 2021 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34329999
10.
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Sci Rep
; 9(1): 5692, 2019 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30952931
11.
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
J Med Chem
; 61(20): 8981-9003, 2018 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-29847930
Resultados
1 -
11
de 11
1
Próxima >
>>